Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

mAbs

Volumn 4, Issue 6, 2012, Pages 724-731

  Mortensen, Deborah L ^a   Prabhu, Saileta ^a   Stefanich, Eric G ^a   Kadkhodayan Fischer, Saloumeh ^a   Gelzleichter, Thomas R ^a   Baker, Dana ^a   Jiang, Jenny ^a   Wallace, Kristin ^a   Iyer, Suhasini ^a   Fielder, Paul J ^a   Putnam, Wendy S ^a  

^a GENENTECH INC   (United States)

Author keywords

Anti IgE; Complex clearance; Fc gamma receptor; Immunoglobulin E; Monoclonal antibody; Pharmacodynamics; Pharmacokinetics

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY HAE 1; MONOCLONAL ANTIBODY HAE 2; OMALIZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; HAPLORHINI; MOUSE; NONHUMAN;

ANTI-IGE; COMPLEX CLEARANCE; FC-GAMMA RECEPTOR; IMMUNOGLOBULIN-E; MONOCLONAL ANTIBODY; PHARMACODYNAMICS; PHARMACOKINETICS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY COMPLEX; ASTHMA; HAPLORHINI; HUMANS; IMMUNOGLOBULIN E; METABOLIC CLEARANCE RATE; MICE; PROTEIN BINDING; RECEPTORS, FC;

EID: 84869798948     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22216     Document Type: Article

References (21)

1. MacGlashan DW Jr., Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Downregulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-45; PMID:9013989
2. Macglashan D Jr. IgE and FcεRI regulation. Ann N Y Acad Sci 2005; 1050:73-88; PMID:16014522; http://dx.doi.org/10.1196/annals.1313.009
3. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19:491-8; PMID:14594521; http://dx.doi.org/10.1185/030079903125002171
4. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68:61-76; PMID:19660004; http://dx.doi.org/10.1111/j.1365-2125.2009.03401.x
5. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan- Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody. AAPS J 2008; 10:425- 30; http://dx.doi.org/10. 1208/s12248-008-9045-4
6. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcγR1, FcγRIII, and FcRn and design of IgG1 variants with improved binding for the FcγR. J Biochem 2001; 276:6591-604
7. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34:10474-82; PMID:7654701; http://dx.doi.org/10.1021/ bi00033a020
8. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279:1000-8; PMID:8930210
9. Schoenhoff M, Bates D, Rupel J, Fei D, Fox JA, Thomas D, et al. Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti IgE antibody in the cynomolgus monkey. J Allergy Clin Immunol 1995; 95:356CS
10. Fox JA, Reitz B, Hagler K, Hsei V, Keller G, Ryan A, et al. Pharmacokinetics and clearance mechanisms of anti-IgE:IgE monoclonal and polyclonal complexes. Pharm Res 1997; 14:217S
11. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10:1093-5; PMID:8378254; http://dx.doi.org/10.1023/A: 1018943613122
12. Sancho J, González E, Escanero JF, Egido J. Binding kinetics of monomeric and aggregated IgG to Kupffer cells and hepatocytes of mice. Immunology 1984; 53:283-9; PMID:6237982
13. Kurlander RJ, Ellison DM, Hall J. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J Immunol 1984; 133:855-62; PMID:6736648
14. Clarkson SB, Kimberly RP, Valinsky JE, Witmer MD, Bussel JB, Nachman RL, et al. Blockade of clearance of immune complexes by an anti-Fc γ receptor monoclonal antibody. J Exp Med 1986; 164:474- 89; PMID:2941515; http://dx.doi.org/10.1084/jem.164.2.474
15. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http://dx.doi.org/10.4161/ mabs.3.1.13799
16. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti- IgE humanized monoclonal antibody in ragweedinduced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-21; PMID:9257795; http://dx.doi.org/10.1016/S0091-6749(97)70202-1
17. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548-61; PMID:17096680; http://dx.doi.org/10.1111/j. 1365-2125.2006.02803.x
18. Meno-Tetang GML, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 2005; 96:182-92; PMID:15733213; http://dx.doi.org/10.1111/j. 1742-7843.2005.pto960307.x
19. Sun Y-N. Advanced methods of PK/PD Systems Analysis. Presented at the Biomedical Simulations Resource Workshop, Marina Del Rey CA, June 22-23, 2001
20. Boswell CA, Deng R, Lin K, Putnam WS, Lei C, Theil FP, et al. In vitro-in vivo correlations of pharmacokinetics, pharmacodynamics and metabolism for antibody therapeutics. Pharmacodynamic and Metabolic Outcomes of Therapeutic Proteins and Peptides, 2009; New York: Informa Healthcare 15-52
21. Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today 2007; 12:1018-24; PMID:18061880; http://dx.doi.org/10.1016/j.drudis.2007.10.002